Both Altimmune Inc. (NASDAQ:ALT) and Dova Pharmaceuticals Inc. (NASDAQ:DOVA) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune Inc.	10.33M	4.04	42.48M	-38.81	0.00
Dova Pharmaceuticals Inc.	10.36M	23.82	72.28M	-2.27	0.00

In table 1 we can see Altimmune Inc. and Dova Pharmaceuticals Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 represents Altimmune Inc. (NASDAQ:ALT) and Dova Pharmaceuticals Inc. (NASDAQ:DOVA)’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Altimmune Inc.	-411.23%	-74.2%	-50.4%
Dova Pharmaceuticals Inc.	-697.68%	-63.8%	-50.2%

Liquidity

The current Quick Ratio of Altimmune Inc. is 1.4 while its Current Ratio is 1.4. Meanwhile, Dova Pharmaceuticals Inc. has a Current Ratio of 7.5 while its Quick Ratio is 7.4. Dova Pharmaceuticals Inc. is better positioned to pay off its short-term and long-term debts than Altimmune Inc.

Insider and Institutional Ownership

Institutional investors owned 11% of Altimmune Inc. shares and 40.5% of Dova Pharmaceuticals Inc. shares. Insiders owned roughly 3.7% of Altimmune Inc.’s shares. Competitively, insiders own roughly 46.9% of Dova Pharmaceuticals Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Altimmune Inc.	-3.97%	-16.61%	-19.64%	-71.4%	-94.39%	29.13%
Dova Pharmaceuticals Inc.	7.51%	8.07%	-45.75%	-67.4%	-71.65%	9.5%

For the past year Altimmune Inc. has stronger performance than Dova Pharmaceuticals Inc.

Summary

On 6 of the 10 factors Dova Pharmaceuticals Inc. beats Altimmune Inc.

Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, designs and develops immunotherapeutic products for treating acute respiratory infections, chronic viral infections, and cancer. The company develops NasoVAX, an intranasally administered recombinant influenza vaccine that has completed Phase I clinical trials; and HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials. Its preclinical stage products include NasoShield, a vaccine for the prevention of anthrax disease following inhalation of pathogen spores; and Oncosyn, an immunotherapeutic for treating solid cancer indications, such as lung, colorectal, melanoma, breast, ovarian, and others. The company was formerly known as Vaxin Inc. Altimmune, Inc. was founded in 1997 and is based in Gaithersburg, Maryland.

Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia diseases. Its drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver diseases. The company was founded in 2016 and is based in Durham, North Carolina.